Proposed mechanism of action (MOA)1

  • Decreased tumor cell proliferation has been demonstrated in vitro

  • NEXAVAR® (sorafenib) was shown to inhibit multiple intracellular (c-CRAF, BRAF, and mutant BRAF) and cell surface kinases (KIT, FLT-3, RET, RET/PTC, VEGFR-1, VEGFR-2, VEGFR-3, and PDGFR–ß)

  • Several of these kinases are thought to be involved in tumor cell signaling, angiogenesis, and apoptosis

  • NEXAVAR inhibited tumor growth and increased tumor apoptosis in models of hepatocellular carcinoma (HCC), renal cell carcinoma (RCC), and differentiated thyroid cancer (DTC)